Malaysian law firm Christopher & Lee Ong (CLO) has merged with two boutiques, technology and data protection specialist Haryati Deepak, and IP firm Kandiah & Sri.

Following the merger, CLO will have 61 lawyers. Deepak Pillai of Haryati Deepak will head its technology and data protection practice, while Sri Sarguna Raj from Kandiah & Sri will lead its intellectual property practice.

Haryati Deepak, a well-recognised technology and data protection practice, has joined CLO from 1 November 2015 while Kandiah & Sri, which is active in the field of intellectual property, will come on board on 1 December 2015.

“We are delighted to welcome Haryati Deepak and Kandiah & Sri to the team. I have no doubt we will benefit considerably from the depth of their experience in technology, data protection and intellectual property, and they will position Christopher & Lee Ong to provide comprehensive counsel across different areas of expertise,” said Lee Hock Chye, joint managing partner of Christopher & Lee Ong, in a statement.

Full-service law firm Christopher & Lee Ong is a part of the Rajah & Tann Asia network.

Related Articles

Appointments

Malaysia’s ASL hires three-partner IP team from CLO

by Nimitt Dixit |

Malaysian law firm Adnan Sundra & Low (ASL) has significantly bolstered its intellectual property capabilities with the addition of a five-member IP, sports, and gaming group from local rival Christopher & Lee Ong (CLO), led by practice head Sri Sarguna Raj.

Appointments

KL: CLO expands IP, IA practice with hires from LAW, Joel & Mei

by Sarah Wong |

Malaysian law firm Christopher & Lee Ong, a member firm of Rajah & Tann Asia, has bolstered its recently rebranded IP & Intangible Assets practice with the hire of partners Celia Cheah Chiew Lan and Sri Richgopinath from LAW Partnership and Joel & Mei, respectively.

Deals

R&T, WongP, Lee & Lee advise on $595 mln TCM deal

by Nimitt Dixit |

Singapore law firms WongPartnership, Lee & Lee and Rajah & Tann (R&T), and R&T’s Malaysian member firm Christopher & Lee Ong have advised traditional Chinese medicine firm Eu Yan Sang International (EYS) and its shareholders on the sale of 86 percent of EYS’ shares.